Page 260 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 260
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0806 THE VALUE OF SURVIVAL BENEFITS FROM TREATING
HEPATITIS C AT DIFFERENT FIBROSIS STAGES WITH
ALL-ORAL, INTERFERON-FREE THERAPY RELATIVE TO
‘WATCHFUL WAITING’
Scott Johnson, Hélène PariséYuri Sanchez Gonzalez*, Alice Wang,
Suchin Virabhak, Timothy Juday, Sammy Saab, The United States
P0807 THE QUALITY OF LIFE JOURNEY FOR PATIENTS WITH
CHRONIC HEPATITIS C: FROM INTERFERON AND
RIBAVIRIN TO INTERFERON-FREE AND RIBAVIRIN-FREE
REGIMENS
Zobair Younossi*, Maria Stepanova, Linda Henry, Fatema Nader,
Haesuk Park, Brian Lam, Huong Pham, Sharon Hunt, The United States
P0808 IMPROVEMENT IN LIVER FUNCTION AND NON-INVASIVE
ESTIMATES OF LIVER FIBROSIS 48 WEEKS AFTER
ePOSTERS TREATMENT WITH OMBITASVIR/PARITAPREVIR/R,
DASABUVIR AND RIBAVIRIN IN HCV GENOTYPE 1
PATIENTS WITH CIRRHOSIS
Heiner Wedemeyer*, Thomas Berg, Steven L. Flamm, Graham R. Foster,
Antonio Craxi, Dominique Larrey, Timothy R. Morgan,
Michael W. Fried, Fred Poordad, Roger Trinh, Sandra Lovell,
Yuanyuan Tang, Marcos Pedrosa, Juan-Carlos Lopez-Talavera,
Ira M. Jacobson, Germany
P0809 98% SVR12 IN KOREAN AND TAIWANESE PATIENTS WITH
CHRONIC GENOTYPE 2 HCV INFECTION RECEIVING 12
WEEKS OF SOFOSBUVIR PLUS RIBAVIRIN: RESULTS FROM
AN INTERNATIONAL, MULTICENTER PHASE 3 STUDY
Jia-Horng Kao*, Sang-Hoon Ahn, Rong-Nan Chien, Sook-Hyang Jeong,
Cheng-Yuan Peng,Young-Suk Lim, Jenny C. Yang, Hongmei Mo,
Ling-Ling Han, Diana Brainard, Steven J. Knox, John G. McHutchison,
Youn-Jae Lee, Ting-Tsung Chang, Seung-Woon Paik, Chi-Jen Chu,
Wan-Long Chuang, Kwang-Hyub Han, Taiwan
260 The International Liver Congress™ 2015 • ILC Programme
P0806 THE VALUE OF SURVIVAL BENEFITS FROM TREATING
HEPATITIS C AT DIFFERENT FIBROSIS STAGES WITH
ALL-ORAL, INTERFERON-FREE THERAPY RELATIVE TO
‘WATCHFUL WAITING’
Scott Johnson, Hélène PariséYuri Sanchez Gonzalez*, Alice Wang,
Suchin Virabhak, Timothy Juday, Sammy Saab, The United States
P0807 THE QUALITY OF LIFE JOURNEY FOR PATIENTS WITH
CHRONIC HEPATITIS C: FROM INTERFERON AND
RIBAVIRIN TO INTERFERON-FREE AND RIBAVIRIN-FREE
REGIMENS
Zobair Younossi*, Maria Stepanova, Linda Henry, Fatema Nader,
Haesuk Park, Brian Lam, Huong Pham, Sharon Hunt, The United States
P0808 IMPROVEMENT IN LIVER FUNCTION AND NON-INVASIVE
ESTIMATES OF LIVER FIBROSIS 48 WEEKS AFTER
ePOSTERS TREATMENT WITH OMBITASVIR/PARITAPREVIR/R,
DASABUVIR AND RIBAVIRIN IN HCV GENOTYPE 1
PATIENTS WITH CIRRHOSIS
Heiner Wedemeyer*, Thomas Berg, Steven L. Flamm, Graham R. Foster,
Antonio Craxi, Dominique Larrey, Timothy R. Morgan,
Michael W. Fried, Fred Poordad, Roger Trinh, Sandra Lovell,
Yuanyuan Tang, Marcos Pedrosa, Juan-Carlos Lopez-Talavera,
Ira M. Jacobson, Germany
P0809 98% SVR12 IN KOREAN AND TAIWANESE PATIENTS WITH
CHRONIC GENOTYPE 2 HCV INFECTION RECEIVING 12
WEEKS OF SOFOSBUVIR PLUS RIBAVIRIN: RESULTS FROM
AN INTERNATIONAL, MULTICENTER PHASE 3 STUDY
Jia-Horng Kao*, Sang-Hoon Ahn, Rong-Nan Chien, Sook-Hyang Jeong,
Cheng-Yuan Peng,Young-Suk Lim, Jenny C. Yang, Hongmei Mo,
Ling-Ling Han, Diana Brainard, Steven J. Knox, John G. McHutchison,
Youn-Jae Lee, Ting-Tsung Chang, Seung-Woon Paik, Chi-Jen Chu,
Wan-Long Chuang, Kwang-Hyub Han, Taiwan
260 The International Liver Congress™ 2015 • ILC Programme
